Barclays
GBT

Barclays’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Barclays’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-51,000
Closed -$4.05M – 6613
2019
Q4 		$4.05M Buy
51,000
+50,000
+5,000% +$2.96M ﹤0.01% 2243
2019
Q3 		$49K Sell
1,000
-34,300
-97% -$1.79M ﹤0.01% 5917
2019
Q2 		$1.86M Buy
35,300
+34,100
+2,842% +$1.96M ﹤0.01% 3015
2019
Q1 		$64K Sell
1,200
-52,300
-98% -$2.57M ﹤0.01% 5699
2018
Q4 		$2.2M Buy
53,500
+45,900
+604% +$1.72M ﹤0.01% 2317
2018
Q3 		$289K Sell
7,600
-34,700
-82% -$1.54M ﹤0.01% 4713
2018
Q2 		$1.91M Buy
42,300
+40,800
+2,720% +$1.86M ﹤0.01% 2625
2018
Q1 		$72K Sell
1,500
-25,700
-94% -$1.43M ﹤0.01% 5622
2017
Q4 		$1.07M Buy
+27,200
New +$1.02M ﹤0.01% 3059
2017
Q3 		– Sell
-2,400
Closed -$66K – 7127
2017
Q2 		$66K Sell
2,400
-35,900
-94% -$1.07M ﹤0.01% 5182
2017
Q1 		$1.41M Buy
+38,300
New +$965K ﹤0.01% 2414

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's GBT Position: Q4 2022 in Review

Barclays sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 130,434 shares — an estimated $8.88M sold.

Barclays first reported a position in GBT in Q3 2015 and held it in 27 quarters. The position peaked at $18.9M in Q2 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Barclays reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 130,434 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $8.88M.
  • Barclays first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 27 quarters.
  • Barclays's Global Blood Therapeutics, Inc. position peaked at $18.9M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.